Category: Pharmaceutical Industry
-
Pfizer, BioNTech hit back against GSK mRNA suits in UPC, Ireland: file UK revocation action
The move does not come as a major surprise, given the pharma companies’ previous success against GlaxoSmithKline in the UK.
-
Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costs
AstraZeneca must reimburse two thirds of the costs of an unsuccessful case Teva, Glenmark and Generics (UK). Separately, Bayer does not have to disgorge profits to Sandoz.
-
Boehringer wins nintedanib PI against Zentiva as UPC CoA reverses Lisbon LD on when infringement is imminent, clarifies how to argue national law
Context: Three months ago, the Unified Patent Court’s (UPC) Lisbon Local Division (LD) denied an application for provisional measures (which in some other jurisdictions would be called a motion for a preliminary injunction (PI)) by Boehringer Ingelheim against Zentiva, holding that an infringement did not appear imminent (item 2 of our May 10, 2025 UPC…
-
BREAKING: GSK cashes in on license deal as CureVac settles U.S. patent dispute with acquirer BioNTech and Pfizer for $790M+
Pfizer and BioNTech have settled their three-year COVID vaccine-related patent infringement dispute with CureVac in the U.S., granting the latter and its licensing partner GSK $370 million each.
-
An interview with Bayer’s outgoing head of IP Dr. Jörg Thomaier, new head Dorian Immler
Following three decades at Bayer, Dr. Jörg Thomaier is retiring as head of IP, super confident that his replacement Dorian Immler will have the energy and drive to make the changes that the department needs to keep prospering.
-
Novo Nordisk suffers loss over negative claim limitation in ongoing patent dispute over diabetes drug Wegovy
The United States District Court for the District of Delaware has ruled that Viatris has not induced the infringement of one of five asserted patents in litigation initiated by Novo Nordisk.
-
U.S. appeals court revokes Novartis short-term injunction in Entresto patent dispute against MSN
Decision allows MSN to launch its generic version of Entresto into the market, and opens the door for others to follow.
-
U.S. appeals court grants Novartis short-term injunction in Entresto patent dispute with MSN: non-skilled-artisan testimony is key issue
The Federal Circuit has granted Novartis a few more days of Entresto exclusivity through a short-term injunction against MSN.
-
EWCA heard Pfizer, BioNTech appeal against Moderna’s COVID vaccine patent win
After losing a major ruling in the High Court of Justice in London last year, Pfizer and BioNTech asked the England & Wales Court of Appeal to overturn a decision finding a key Moderna COVID patent was valid and infringed.
-
Novartis denied injunctive relief against MSN in chronic heart failure patent fight: next stop emergency motion for injunction pending appeal?
Novartis cannot block rival MSN Pharmaceuticals from launching a generic version of its chronic heart failure treatment Entresto before its patent expires in November 2026, the District of Delaware has held.